MorphoSys AG has announced that Shionogi & Co Ltd, Osaka, Japan, has elected to expand its current research license to cover the use of MorphoSys’s HuCAL PLATINUM technology in a drug discovery. HuCAL PLATINUM is the latest and most powerful MorphoSys antibody library. During this test period, Shionogi was able to compare HuCAL PLATINUM with its predecessor HuCAL GOLD, and found the new library to be considerably better.

The Texas Sinus Center announced it is now offering the FinESS® Sinus Treatment, a minimally invasive treatment that breaks the cycle of chronic sinusitis (CRS) at Foundation Surgical Hospital of San Antonio. Developed by Minnesota-based Entellus® Medical, Inc., FinESS is an effective treatment that results in less pain, bleeding and recovery time for patients. In most cases, patients are back to their normal routine within hours.

For the full story, Click Here

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI). Allergic rhinitis is the third most common chronic disease in children, affecting up to 40 percent of the population.

For the full article, Click Here

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body’s sticky and viscous mucus secretions to deliver a sustained-release medication cargo. The researchers say these nanoparticles, which degrade over time into harmless components, could one day carry life-saving drugs to patients suffering from dozens of health conditions, including diseases of the eye, lung, gut or female reproductive tract.

For the full story, Click Here